Stocks & ETFs Screener: 200+ results (Biotechnology)
| Symbol | Industry | Market Cap | Fund. Score | Div. Score | Tech. Score | P/E | Return 12m vs S&P 500 |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie |
Biotechnology
Biologics, Immunology, Oncology |
404B | 48.1% | 73.8% | 82.3% | 175 | 14.3% |
| AMGN Amgen |
Biotechnology
Biologics, Oncology, Osteoporosis |
183B | 81.9% | 68.2% | 52.4% | 26.3 | 2.09% |
| GILD Gilead Sciences |
Biotechnology
HIV, COVID-19, Hepatitis, Oncology |
152B | 83.3% | 65.7% | 80.2% | 19.0 | 18.7% |
| VRTX Vertex |
Biotechnology
Cystic Fibrosis, Gene Therapy |
117B | 86.9% | - | 25.3% | 32.1 | -19.4% |
| REGN Regeneron |
Biotechnology
Eye, Dermatology, Asthma, Cancer |
76.6B | 75.9% | 15.0% | -12.5% | 17.3 | -22.7% |
| ARGX argenx |
Biotechnology
FcgRn-Blocker, MusK-Agonist |
57.0B | 71.2% | - | 82.4% | 39.1 | 27.3% |
| ALNY Alnylam |
Biotechnology
ONPATTRO, AMVUTTRA, GIVLAARI |
56.8B | 61.7% | - | 81.6% | - | 41.9% |
| HLN Haleon |
Biotechnology
Toothpaste, Vitamins, Cold-Relief |
44.0B | 60.2% | 53.5% | 30.9% | 22.3 | -14.0% |
| INSM Insmed |
Biotechnology
Inhaled Antibiotic, DPP1 |
43.5B | 32.6% | - | 88.2% | - | 133% |
| ONC BeiGene |
Biotechnology
BTK Inhibitor, PD-1 Antibody, PARP |
37.4B | 64.5% | - | 56.9% | 662 | 34.3% |
| NTRA Natera |
Biotechnology
Panorama, Horizon, Signatera |
33.4B | 47.9% | - | 73.5% | - | 22.8% |
| BIIB Biogen |
Biotechnology
Multiple Sclerosis, Spinal |
25.9B | 66.6% | - | -33.7% | 16.1 | -1.70% |
| 22UA BioNTech SE |
Biotechnology
Cancer Vaccines, mRNA Therapies |
24.0B | 17.9% | 1.0% | -64.5% | - | -35.9% |
| BNTX BioNTech SE |
Biotechnology
Oncology Vaccines,Checkpoint |
23.4B | 13.0% | 1.0% | -60.8% | - | -30.6% |
| UTHR United Therapeutics |
Biotechnology
Treprostinil, Treprostinil |
22.0B | 92.0% | - | 69.0% | 18.1 | 13.5% |
| INCY Incyte |
Biotechnology
JAKAFI, MONJUVI, PEMAZYRE |
20.0B | 90.1% | - | 30.4% | 17.3 | 15.4% |
| GMAB Genmab AS |
Biotechnology
Antibody, Cancer, Lymphoma |
19.8B | 78.4% | - | -1.49% | 14.0 | 22.4% |
| EXAS EXACT Sciences |
Biotechnology
Colorectal, Breast, Colon |
19.2B | 47.4% | - | 43.6% | - | 43.3% |
| RVMD Revolution |
Biotechnology
RAS Inhibitors, Companion |
15.2B | 25.0% | - | 70.1% | - | 44.7% |
| BIM Biomerieux |
Biotechnology
Diagnostic, Instruments, Reagents |
15.1B | 78.1% | 60.4% | 15.1% | 34.6 | -6.32% |
| ROIV Roivant Sciences |
Biotechnology
Antibody, Small-Molecule, Inhaled |
14.7B | 31.5% | - | 86.0% | - | 46.2% |
| BBIO BridgeBio Pharma |
Biotechnology
TTR Stabilizer, FGFR Inhibitor |
14.4B | 44.9% | - | 83.1% | - | 112% |
| NBIX Neurocrine |
Biotechnology
Movement, Endocrine |
14.1B | 85.8% | - | 47.9% | 33.6 | 5.01% |
| SMMT Summit Therapeutics |
Biotechnology
Antibody, Immunotherapy, Oncology |
13.7B | 43.2% | - | 44.5% | - | -20.2% |
| MDGL Madrigal |
Biotechnology
Rezdiffra, Liver Therapy, MASH |
13.4B | 55.5% | - | 85.2% | - | 52.1% |
| IONS Ionis |
Biotechnology
Triglyceride, Amyloidosis, SMA |
13.2B | 19.8% | 0.21% | 73.7% | - | 78.8% |
| ASND Ascendis Pharma AS |
Biotechnology
Growth Hormone |
12.7B | 35.8% | - | 72.5% | - | 29.9% |
| ERF Eurofins |
Biotechnology
Testing, Laboratory, Services |
12.2B | 70.1% | 2.87% | 7.62% | 26.0 | 4.99% |
| EXEL Exelixis |
Biotechnology
Cabozantinib, Cobimetinib |
11.7B | 93.0% | - | 80.2% | 18.3 | 4.13% |
| BMRN Biomarin |
Biotechnology
Enzyme, Replacement, Therapy |
10.6B | 86.0% | - | -74.6% | 20.5 | -29.7% |
| MRNA Moderna |
Biotechnology
Vaccines, Oncology, Rare-Diseases |
9.44B | 22.6% | - | -84.5% | - | -45.9% |
| ARWR Arrowhead |
Biotechnology
Plozasiran, Olpasiran, Fazirsiran |
8.94B | 49.2% | - | 42.8% | - | 159% |
| ABVX Abivax American |
Biotechnology
Obefazimod, Immunoregulatory |
8.19B | 38.7% | - | 78.5% | - | 1,166% |
| CYTK Cytokinetics |
Biotechnology
Cardiac Activator, Skeletal |
8.14B | 35.4% | - | 47.4% | - | 6.69% |
| ABVX Abivax |
Biotechnology
Immunomodulator, Inflammatory |
8.11B | 42.5% | - | 71.9% | - | 1,051% |
| NUVL Nuvalent |
Biotechnology
ROS1 Inhibitor, ALK Inhibitor |
7.84B | 28.9% | - | 74.2% | - | -2.12% |
| GRFS Grifols |
Biotechnology
Immunoglobulin, Albumin |
7.65B | 65.1% | 40.7% | 25.0% | 13.8 | 7.87% |
| HALO Halozyme |
Biotechnology
Enzyme, Cancer, Immunodeficiency |
7.60B | 92.3% | - | 39.2% | 14.1 | 10.3% |
| RYTM Rhythm |
Biotechnology
Setmelanotide, Rare Obesity, MC4R |
7.02B | 42.2% | - | 93.7% | - | 53.4% |
| CDTX Cidara Therapeutics |
Biotechnology
Antifungal, Antiviral, Oncology |
6.92B | 23.5% | - | 80.2% | - | 756% |
| KRYS Krystal Biotech |
Biotechnology
Gene, Therapy, Topical, Wound, Skin |
6.44B | 89.0% | - | 72.3% | 33.2 | 11.3% |
| RGC Regencell |
Biotechnology
TCM Formulations, Neurocognitive |
6.43B | 37.2% | - | 77.6% | - | -12.5% |
| PTCT PTC Therapeutics |
Biotechnology
Translarna, Emflaza, Upstaza |
6.20B | 65.7% | - | 59.3% | 8.98 | 33.7% |
| COGT Cogent Biosciences |
Biotechnology
Kinase Inhibitor, FGFR Inhibitor |
6.10B | 49.6% | - | 67.2% | - | 249% |
| PCVX Vaxcyte |
Biotechnology
Pneumococcal, Streptococcus |
6.08B | 27.0% | - | -13.1% | - | -57.5% |
| BLTE Belite Bio |
Biotechnology
Oral Therapy, Stargardt |
5.67B | 32.4% | - | 90.2% | - | 98.5% |
| CRSP Crispr Therapeutics |
Biotechnology
Gene-Edited Cell Therapy, CAR T |
5.47B | 32.2% | - | 20.9% | - | 0.10% |
| PTGX Protagonist |
Biotechnology
Peptide, Hematology, Inflammation |
5.46B | 63.8% | - | 90.1% | 132 | 91.3% |
| APGE Apogee |
Biotechnology
Monoclonal Antibody, Atopic |
5.09B | 35.4% | - | 70.0% | - | 33.2% |
| TGTX TG Therapeutics |
Biotechnology
Briumvi, Ublituximab, BTK |
5.09B | 67.3% | - | 34.7% | 11.6 | -19.0% |
| LEGN Legend Biotech |
Biotechnology
CAR-T, Oncology, Myeloma |
5.08B | 29.0% | - | -56.1% | - | -49.8% |
| CELC Celcuity |
Biotechnology
Cancer Test, Therapy Candidate |
4.90B | 24.9% | - | 80.2% | - | 601% |
| ALKS Alkermes |
Biotechnology
Schizophrenia, Bipolar, Alcohol |
4.77B | 89.8% | - | 2.10% | 14.4 | -20.6% |
| KYMR Kymera Therapeutics |
Biotechnology
IRAK4, STAT6, TYK2, Protein |
4.77B | 28.4% | - | 70.9% | - | 74.1% |
| PRAX Praxis Precision |
Biotechnology
Ulixacaltamide, Vormatrigine |
4.75B | 30.8% | - | 55.0% | - | 239% |
| ADMA ADMA Biologics |
Biotechnology
IVIG, Immune Globulin, Hepatitis |
4.72B | 84.9% | - | 51.0% | 23.0 | -8.90% |
| NAMS NewAmsterdam |
Biotechnology
Obicetrapib, Ezetimibe, CETP |
4.70B | 26.9% | - | 80.9% | - | 64.4% |
| ACAD ACADIA |
Biotechnology
Antipsychotic, Rett |
4.53B | 86.2% | - | 56.3% | 17.3 | 25.4% |
| CRNX Crinetics |
Biotechnology
Paltusotine, Atumelnant, CRN09682 |
4.50B | 21.7% | - | 48.3% | - | -26.0% |
| SRRK Scholar Rock |
Biotechnology
Monoclonal Antibodies, Inhibitor |
4.44B | 26.4% | - | 34.5% | - | -14.2% |
| INDV Indivior Ordinary |
Biotechnology
Suboxone, Sublocade, Subutex, Opvee |
4.33B | 74.1% | 2.63% | 63.9% | 35.3 | 175% |
| CNTA Centessa |
Biotechnology
OX2R Agonist, Neurological Drugs |
4.23B | 33.4% | - | 74.7% | - | 38.5% |
| ACLX Arcellx |
Biotechnology
Anitocabtagene Autoleucel |
4.22B | 40.0% | - | 60.0% | - | -25.3% |
| IMVT Immunovant |
Biotechnology
Monoclonal Antibodies, Autoimmune |
4.09B | 25.8% | - | 21.8% | - | -30.6% |
| GRAL GRAIL |
Biotechnology
Cancer Screening, Diagnostic Aid |
4.08B | 40.6% | - | 91.7% | - | 291% |
| VKTX Viking Therapeutics |
Biotechnology
VK2809, VK2735, VK5211, VK0214 |
3.91B | 40.5% | - | 49.3% | - | -35.2% |
| ARQT Arcutis |
Biotechnology
Topical Cream, Topical Foam, JAK1 |
3.82B | 41.9% | - | 51.0% | - | 107% |
| LGND Ligand |
Biotechnology
Infectious, Oncology, Nephrology |
3.71B | 49.9% | 0.14% | 84.5% | 82.7 | 39.7% |
| MIRM Mirum |
Biotechnology
LIVMARLI, Cholbam, Chenodal |
3.65B | 47.4% | - | 92.4% | - | 32.1% |
| IRON Disc Medicine |
Biotechnology
Porphyria Drug, Anemia Drug |
3.54B | 36.4% | - | 49.8% | - | 24.1% |
| RARE Ultragenyx |
Biotechnology
Biologic, Gene Therapy, Antibody |
3.52B | 36.5% | - | -56.5% | - | -35.6% |
| VCYT Veracyte |
Biotechnology
Thyroid, Prostate, Bladder |
3.51B | 63.4% | - | 19.6% | 117 | -10.3% |
| CGON CG Oncology |
Biotechnology
Oncolytic Virus, Immunotherapy |
3.49B | 32.3% | - | 23.8% | - | 9.86% |
| XENE Xenon |
Biotechnology
Kv7 Opener, Phase 3, Epilepsy |
3.44B | 29.6% | - | 19.0% | - | -9.48% |
| TVTX Travere |
Biotechnology
Medication, Tablets, Enzyme |
3.16B | 27.5% | - | 44.0% | - | 60.8% |
| KNSA Kiniksa |
Biotechnology
ARCALYST, Vixarelimab, KPL-387 |
3.16B | 66.8% | - | 94.2% | 92.6 | 68.8% |
| IDYA Ideaya Biosciences |
Biotechnology
Oncology, Kinase, Inhibitor, ADC |
3.16B | 22.9% | - | 62.4% | - | 7.49% |
| RCUS Arcus Biosciences |
Biotechnology
Cancer, Immunotherapy |
3.13B | 29.9% | - | -9.01% | - | 25.5% |
| VRDN Viridian |
Biotechnology
Monoclonal Antibody, Thyroid Eye |
3.10B | 46.9% | - | 30.6% | - | 42.4% |
| FOLD Amicus Therapeutics |
Biotechnology
Galafold, Pombiliti, Opfolda, Gene |
3.05B | 52.6% | - | -25.2% | - | -12.7% |
| MLYS Mineralys |
Biotechnology
Phase II Inhibitor, Oral |
3.02B | 30.8% | - | 71.9% | - | 141% |
| APLS Apellis |
Biotechnology
Therapeutic, Complement |
2.99B | 76.1% | - | -59.8% | 65.6 | -40.6% |
| DYN Dyne Therapeutics |
Biotechnology
Antisense Oligos, FORCE Platform |
2.94B | 29.6% | - | 12.6% | - | -43.8% |
| VERA Vera Therapeutics |
Biotechnology
Atacicept, Mab, Dual-Inhibitor |
2.88B | 24.1% | 3.50% | 29.9% | - | -17.8% |
| CPRX Catalyst |
Biotechnology
Firdapse, Fycompa, Ruzurgi, Agamree |
2.85B | 91.5% | - | 18.9% | 13.5 | -9.28% |
| DNLI Denali Therapeutics |
Biotechnology
RIPK1 Inhibitor, eIF2B Activator |
2.78B | 25.0% | - | -54.0% | - | -31.1% |
| BEAM Beam Therapeutics |
Biotechnology
Base-Editing Therapeutics, Sickle |
2.75B | 27.5% | - | -48.5% | - | -15.8% |
| SLNO Soleno Therapeutics |
Biotechnology
Diazoxide, Choline, Tablet, Rare |
2.75B | 41.4% | - | 66.0% | - | -8.72% |
| NUVB Nuvation Bio |
Biotechnology
Taletrectinib, Safusidenib |
2.75B | 36.3% | - | 64.4% | - | 150% |
| SYRE Spyre Therapeutics |
Biotechnology
Monoclonal Antibodies |
2.60B | 29.9% | - | 36.4% | - | 9.88% |
| RXRX Recursion |
Biotechnology
Drug Discovery Platform |
2.51B | 30.1% | - | -68.5% | - | -49.6% |
| EWTX Edgewise |
Biotechnology
EDG-5506, EDG-7500, Oral |
2.49B | 30.0% | - | 19.0% | - | -32.5% |
| IBRX Immunitybio |
Biotechnology
Immunotherapy, Vaccine, Cytokine |
2.32B | 65.8% | - | -75.9% | - | -59.6% |
| NNNN Anbio |
Biotechnology
Antigen Tests, Immunoassay |
2.32B | 66.4% | - | 84.1% | 858 | 420% |
| OLMA Olema |
Biotechnology
Palazestrant, OP-3136, KAT6 |
2.24B | 34.9% | - | 65.1% | - | 146% |
| ZLAB Zai Lab |
Biotechnology
Oncology, Immunology |
2.11B | 30.9% | - | -51.8% | - | -43.4% |
| GLPG Galapagos |
Biotechnology
Medicine, Oncology, Immunology |
2.11B | 37.8% | - | 3.32% | - | 3.30% |
| GPCR Structure |
Biotechnology
GSBR-1290, ACCG-2671, ANPA-0073 |
2.10B | 31.2% | - | 46.0% | - | 68.1% |
| GLPG Galapagos |
Biotechnology
CAR-T, Oncology, Immunology |
2.09B | 25.2% | - | -15.6% | - | -7.08% |
| AUPH Aurinia |
Biotechnology
Immunosuppressant, Lupus |
2.07B | 93.8% | - | 64.5% | 28.0 | 48.8% |
| SRPT Sarepta |
Biotechnology
RNA Therapeutics, Duchenne |
2.07B | 30.4% | - | -75.5% | - | -85.0% |
| ZYME Zymeworks Common |
Biotechnology
Zanidatamab, Bispecific Antibody |
2.01B | 29.8% | - | 71.0% | - | 71.8% |
| CLDX Celldex |
Biotechnology
Antibody, Monoclonal, Bispecific |
1.98B | 40.4% | - | -9.82% | - | -6.94% |
| MESO Mesoblast |
Biotechnology
Stem-Cell Therapy, Inflammation |
1.94B | 36.8% | - | 44.4% | - | 51.4% |
| IMCR Immunocore Holdings |
Biotechnology
Immunotherapy, Oncology, Melanoma |
1.93B | 41.1% | - | 0.43% | - | 0.62% |
| ZBIO Zenas BioPharma |
Biotechnology
Bifunctional Monoclonal Antibody |
1.91B | 31.4% | - | 88.0% | 2.61 | 233% |
| TWST Twist Bioscience |
Biotechnology
Synthetic DNA, Gene Fragments |
1.91B | 35.8% | - | -32.3% | - | -46.5% |
| VCEL Vericel Ord |
Biotechnology
Cartilage, Skin, Burn, Autologous |
1.89B | 61.9% | - | -7.37% | 143 | -40.4% |
| DNTH Dianthus |
Biotechnology
Monoclonal Antibody, C1s |
1.87B | 27.1% | - | 52.8% | - | 57.1% |
| IMNM Immunome |
Biotechnology
Gamma Secretase Inhibitor, ADC |
1.84B | 45.2% | - | 63.7% | - | 14.7% |
| SION Sionna |
Biotechnology
Galicaftor, Navocaftor, SION-109 |
1.82B | 36.9% | - | 92.2% | - | 103% |
| STOK Stoke Therapeutics |
Biotechnology
Antisense, Oligonucleotide |
1.77B | 73.2% | - | 66.2% | 43.6 | 93.7% |
| QURE Uniqure |
Biotechnology
Gene Therapy, Hemophilia B |
1.73B | 36.0% | - | 11.5% | - | 149% |
| ALVO Alvotech |
Biotechnology
Biosimilar, Autoimmune, Oncology |
1.72B | 36.6% | - | -55.5% | 24.0 | -56.9% |
| NRIX Nurix Therapeutics |
Biotechnology
BTK Degrader, IRAK4 Degrader |
1.71B | 35.8% | - | -0.65% | - | -17.2% |
| SNDX Syndax |
Biotechnology
Menin Inhibitor, CSF-1R Antibody |
1.66B | 36.6% | - | -1.20% | - | 9.67% |
| PHVS Pharvaris BV |
Biotechnology
Bradykinin, Antagonist |
1.65B | 24.4% | - | 68.8% | - | 13.4% |
| AGIO Agios Pharm |
Biotechnology
Mitapivat, Tebapivat, AG-181 |
1.59B | 34.6% | - | -10.9% | - | -51.7% |
| MNKD MannKind |
Biotechnology
Inhaled Insulin, Insulin Delivery |
1.56B | 64.0% | - | 1.53% | 50.7 | -24.2% |
| BCRX BioCryst |
Biotechnology
Antiviral, Hae, Complement, Protein |
1.50B | 71.6% | - | -36.9% | - | -13.6% |
| MEDCL Medincell |
Biotechnology
Schizophrenia, Postoperative Pain |
1.48B | 53.1% | - | 83.9% | - | 38.0% |
| ATAI ATAI Life Sciences |
Biotechnology
Psychedelic, Serotonergic |
1.47B | 38.1% | - | 44.1% | - | 141% |
| BTX BlackRock |
Biotechnology
Tech, Private Equity, Mutual Fund |
1.44B | 34.0% | 87.9% | 17.7% | 56.1 | -15.2% |
| ARDX Ardelyx |
Biotechnology
IBS-C Therapy, Phosphate |
1.43B | 33.7% | - | 52.5% | - | -3.74% |
| MBX MBX Biosciences |
Biotechnology
Hypoparathyroidism, Hypoglycemia |
1.41B | 32.7% | - | 60.5% | 4.09 | 9.87% |
| TNGX Tango Therapeutics |
Biotechnology
PRMT5 Inhibitor, Glioblastoma |
1.40B | 32.3% | - | 34.3% | - | 148% |
| TSHA Taysha Gene |
Biotechnology
Gene Therapy, Rett Syndrome, CLN1 |
1.38B | 46.7% | - | 58.2% | - | 81.4% |
| CAPR Capricor |
Biotechnology
Cell Therapy, Exosome Platform |
1.37B | 28.3% | - | 40.0% | - | 58.8% |
| PGEN Precigen |
Biotechnology
Gene Therapy, UltraCAR-T |
1.36B | 34.7% | - | 56.5% | - | 282% |
| DVAX Dynavax |
Biotechnology
Hepatitis Vaccine, Adjuvant |
1.34B | 38.2% | - | -28.9% | - | -25.8% |
| ORKA Oruka Therapeutics |
Biotechnology
Monoclonal Antibody |
1.34B | 28.8% | 1.0% | 51.8% | - | 17.0% |
| RLAY Relay Therapeutics |
Biotechnology
RLY-2608, Lirafugratinib |
1.32B | 47.4% | - | -24.1% | - | 41.1% |
| SVRA Savara |
Biotechnology
Molgramostim, Proteinosis |
1.32B | 23.0% | - | 79.5% | - | 58.5% |
| KOD Kodiak Sciences |
Biotechnology
Anti-VEGF, Biopolymer Conjugate |
1.29B | 46.2% | - | 52.1% | - | 116% |
| BHVN Biohaven |
Biotechnology
Troriluzole, Taldefgrobep |
1.28B | 31.9% | - | -54.4% | - | -78.8% |
| UPB Upstream Bio |
Biotechnology
Clinical-Stage, Therapeutic |
1.26B | 38.1% | - | 66.4% | - | 11.8% |
| IMTX Immatics |
Biotechnology
TCR Cell Therapy, Bispecific |
1.26B | 21.7% | - | 19.4% | - | 13.3% |
| OCS Oculis Holding |
Biotechnology
OCS-01, OCS-02, OCS-05 |
1.25B | 25.7% | - | 61.5% | - | 9.70% |
| XNCR Xencor |
Biotechnology
Monoclonal Antibodies, Bispecific |
1.24B | 12.6% | - | -57.9% | - | -41.7% |
| SANA Sana Biotechnology |
Biotechnology
Allogeneic Islet Therapy, CAR-T |
1.23B | 35.2% | - | 16.1% | - | 43.6% |
| ANAB AnaptysBio |
Biotechnology
Antibody, Autoimmune |
1.21B | 24.4% | - | 53.2% | - | 67.4% |
| TYRA Tyra Biosciences |
Biotechnology
FGFR Inhibitor, Precision |
1.18B | 28.9% | - | 50.9% | - | 20.9% |
| CVAC CureVac |
Biotechnology
Mrna, Vaccines, Oncology |
1.16B | 26.6% | - | -4.46% | 7.82 | 32.9% |
| PHARM Pharming |
Biotechnology
Recombinant C1-Inhibitor |
1.16B | 66.7% | - | 45.8% | - | 57.1% |
| MNMD Mind Medicine |
Biotechnology
MM120, MM402, Anxiety, ADHD, Autism |
1.16B | 31.4% | - | 70.1% | - | 50.1% |
| URGN UroGen Pharma |
Biotechnology
Jelmyto, UGN-102, UGN-103 |
1.14B | 48.5% | - | 67.5% | - | 63.1% |
| CSTL Castle Biosciences |
Biotechnology
Melanoma, Squamous, Uveal |
1.13B | 53.5% | - | 23.1% | - | 8.23% |
| GLUE Monte Rosa |
Biotechnology
MRT-2359, MRT-6160, MRT-8102, CDK2 |
1.12B | 71.3% | - | 35.2% | 53.9 | 45.7% |
| PVLA Palvella |
Biotechnology
Rapamycin, Gel, Microcystic |
1.11B | 25.5% | - | 36.0% | - | 423% |
| NVAX Novavax |
Biotechnology
Vaccine, Adjuvant, Nanoparticle |
1.10B | 40.4% | - | -53.1% | 3.37 | -35.8% |
| NTLA Intellia |
Biotechnology
In-Vivo CRISPR, CAR-T, NK Cell |
1.09B | 32.6% | - | -62.9% | - | -44.4% |
| ABCL Abcellera Biologics |
Biotechnology
Antibody, Metabolic, Autoimmune |
1.07B | 15.6% | - | -20.4% | - | 9.11% |
| ORIC Oric |
Biotechnology
ORIC-114, ORIC-944, ORIC-533 |
1.07B | 35.0% | - | 55.3% | - | -6.55% |
| OPK Opko Health |
Biotechnology
Diagnostics, Laboratory-Testing |
1.05B | 21.0% | - | -29.5% | - | -24.7% |
| KURA Kura Oncology |
Biotechnology
Menin Inhibitor, Farnesyl |
1.04B | 53.8% | - | -14.2% | - | -11.4% |
| AVBP ArriVent |
Biotechnology
Firmonertinib, ARR-217, ARR-002 |
1.02B | 40.1% | - | 7.35% | - | -22.3% |
| NBTX Nanobiotix |
Biotechnology
Nanoparticles, Radiotherapy |
1.01B | 49.1% | - | 76.9% | - | 520% |
| NANO Nanobiotix S.A |
Biotechnology
Nanoparticle, Radiotherapy |
1.01B | 36.1% | - | 75.5% | - | 419% |
| MDXG MiMedx |
Biotechnology
Placental Allografts, Wound Care |
1.00B | 86.1% | - | 15.0% | 25.1 | -36.2% |
| JANX Janux Therapeutics |
Biotechnology
JANX007, JANX008, TRACTr, TRACIr |
997M | 33.3% | - | -19.6% | - | -77.7% |
| BCAX Bicara |
Biotechnology
Ficerafusp Alfa, Bifunctional |
995M | 29.8% | - | -6.56% | 3.38 | -22.6% |
| SPRY ARS |
Biotechnology
Epinephrine, Nasal Spray |
988M | 29.8% | - | -7.30% | - | -34.8% |
| MLTX MoonLake |
Biotechnology
Nanobody, IL-17A, IL-17F |
978M | 26.9% | - | 12.8% | - | -75.9% |
| CDNA CareDx |
Biotechnology
AlloSure, AlloMap, AlloSeq |
956M | 50.2% | - | -16.6% | 14.0 | -32.4% |
| CMPX Compass |
Biotechnology
Tovecimig, CTX-471, CTX-8371 |
953M | 33.0% | - | 34.5% | - | 172% |
| ESPR Esperion |
Biotechnology
Bempedoic Acid, Ezetimibe Combo |
927M | 55.8% | - | -17.0% | - | -13.5% |
| RAPT RAPT Therapeutics |
Biotechnology
CCR4 Antagonist, Inflammation |
922M | 27.9% | - | -18.8% | - | 230% |
| IOVA Iovance |
Biotechnology
Amtagvi, Lifileucel, Proleukin |
917M | 42.7% | - | -80.5% | - | -78.0% |
| GHRS GH Research |
Biotechnology
Mebufotenin, Depression |
907M | 24.8% | - | 39.3% | - | 46.4% |
| RIGL Rigel |
Biotechnology
Kinase, Inhibitor |
888M | 92.4% | - | 69.8% | 7.90 | 59.9% |
| RZLT Rezolute |
Biotechnology
Antibody, Hyperinsulinism |
886M | 36.8% | - | 74.0% | - | 71.6% |
| LENZ LENZ Therapeutics |
Biotechnology
Ophthalmic, Presbyopia, Clinical |
876M | 39.6% | 1.0% | 18.5% | - | -30.1% |
| ABUS Arbutus Biopharma |
Biotechnology
RNAi Therapeutic, PD-L1 Inhibitor |
869M | 29.4% | - | 57.8% | - | 6.0% |
| ALMS Alumis |
Biotechnology
TYK2 Inhibitor, Psoriasis, Lupus |
866M | 50.9% | - | -44.1% | - | 16.1% |
| VIR Vir Biotechnology |
Biotechnology
HDV, RSV, HPV, Coronavirus, TCE |
851M | 28.5% | - | -75.4% | - | -33.2% |
| REPL Replimune |
Biotechnology
Oncolytic Immunotherapy, RP1, RP2 |
842M | 28.2% | - | -71.5% | - | -28.7% |
| ERAS Erasca |
Biotechnology
Naporafenib, ERAS-0015, ERAS-4001 |
820M | 34.9% | - | -21.3% | - | -3.14% |
| IVA Inventiva S.A |
Biotechnology
Lanifibranor, Odiparcil, TGF-Beta |
814M | 46.2% | - | 7.93% | - | 32.1% |
| DAWN Day One |
Biotechnology
Tovorafenib, DAY301, VRK1 Inhibitor |
813M | 30.8% | - | -67.4% | - | -46.4% |
| GERN Geron |
Biotechnology
Telomerase Inhibitor |
811M | 27.3% | - | -64.2% | - | -73.0% |
| VSTM Verastem |
Biotechnology
Avutometinib, Defactinib |
801M | 37.7% | - | 47.4% | - | 61.2% |
| GOSS Gossamer Bio |
Biotechnology
Seralutinib, GB002, PAH Therapy |
789M | 36.0% | - | 43.8% | - | 294% |
| VLA Valneva SE |
Biotechnology
Japanese Encephalitis, Cholera |
764M | 25.5% | - | -9.55% | - | 68.1% |
| PRME Prime Medicine |
Biotechnology
Gene Editing, Prime Editing |
760M | 40.6% | - | -23.3% | - | 13.8% |
| ATXS Astria Therapeutics |
Biotechnology
Monoclonal, Antibody, Plasma |
749M | 35.6% | - | 20.4% | - | 12.7% |
| CGEM Cullinan Oncology |
Biotechnology
Zipalertinib, CLN-978, CLN-619 |
735M | 31.1% | - | -24.2% | - | -14.9% |
| LXEO Lexeo |
Biotechnology
Gene Therapy, Cardiomyopathy |
720M | 33.8% | - | -3.82% | - | 0.33% |
| MGTX MeiraGTx Holdings |
Biotechnology
Gene Therapy, Ocular Diseases |
697M | 36.3% | - | 36.2% | - | 13.9% |
| CTMX CytomX Therapeutics |
Biotechnology
Antibody-Drug Conjugate, T-Cell |
691M | 60.9% | - | 53.6% | 13.6 | 170% |
| PROK ProKidney |
Biotechnology
Cell Therapy, Autologous Renal |
680M | 40.9% | - | -27.9% | - | -3.83% |
| KALV Kalvista |
Biotechnology
Plasma Kallikrein Inhibitor, Oral |
675M | 39.7% | - | 64.6% | - | 51.3% |
| RGNX Regenxbio |
Biotechnology
Gene,Therapy,AAV,Platform,Pipeline |
670M | 14.7% | - | -14.5% | - | 9.39% |
| CRVS Corvus |
Biotechnology
Kinase Inhibitor, Adenosine |
658M | 33.8% | - | 66.5% | - | -6.96% |
| MYGN Myriad Genetics |
Biotechnology
Hereditary-Cancer, Risk |
654M | 35.8% | 0.08% | -74.6% | - | -56.8% |
| ANNX Annexon |
Biotechnology
Antibody, Fragment |
638M | 36.7% | - | -16.5% | - | -14.3% |
| FDMT 4D Molecular |
Biotechnology
4D-150, 4D-710, 4D-175, 4D-725 |
633M | 27.5% | - | -16.2% | - | 28.0% |
| IRWD Ironwood |
Biotechnology
Linaclotide, Apraglutide, IW-3300 |
607M | 57.8% | - | -52.1% | 20.7 | -20.7% |
| EBS Emergent |
Biotechnology
Vaccine, Antitoxin, Auto-Injector |
596M | 50.4% | 0.14% | 3.09% | 8.46 | 16.0% |
| PRTA Prothena |
Biotechnology
Neurodegeneration, Antibody |
596M | 28.3% | - | -71.0% | - | -37.2% |
| ASMB Assembly |
Biotechnology
Antiviral, Small-Molecule |
592M | 33.9% | - | 60.1% | - | 86.9% |